Accelerator Life Science Partners

Accelerator Life Science Partners is a venture capital firm focused on incubating and investing in early-stage companies within the life sciences, biotechnology, and therapeutics sectors. Established in 2003, the firm operates from offices in Seattle and New York City, with an additional presence in San Diego. Accelerator Life Science Partners typically invests up to $2 million per company, primarily targeting investments in New York City and Seattle. The firm does not engage in subsequent financing rounds and generally maintains its investments for 12 to 24 months.

Alice Chen

Executive Vice President

Andrew Howard

Operating Partner

Merika Koday Ph.D

Principal

Francisco D. Salva

Operating Partner

Melissa A. Yeager

Operating Partner

2 past transactions

KayoThera

Series A in 2022
KayoThera is a biotechnology company based in Princeton, New Jersey, focused on developing therapeutics for late-stage and metastatic cancers. Founded in 2019, the company aims to create first-in-class immuno- and targeted therapies that target a key enzyme responsible for protecting cancer cells, as well as depleting regulatory T-cells. This innovative approach seeks to enhance the effectiveness of existing treatments, such as chemotherapy and immunotherapy, thereby offering new hope to patients with previously incurable cancers. KayoThera's mission is centered on driving breakthroughs in cancer treatment and improving patient outcomes.

Magnolia Neurosciences

Series A in 2018
Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.